RhumbLine Advisers’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $239K | Sell |
16,344
-517
| -3% | -$7.66K | ﹤0.01% | 3193 |
|
|
2026
Q1 | $244K | Sell |
16,861
-1,284
| -7% | -$14.9K | ﹤0.01% | 3028 |
|
|
2025
Q4 | $174K | Sell |
18,145
-2,174
| -11% | -$20.8K | ﹤0.01% | 3236 |
|
|
2025
Q3 | $191K | Sell |
20,319
-907
| -4% | -$8.66K | ﹤0.01% | 3243 |
|
|
2025
Q2 | $225K | Buy |
21,226
+115
| +0.5% | +$1.45K | ﹤0.01% | 3164 |
|
|
2025
Q1 | $317K | Sell |
21,111
-1,136
| -5% | -$18.9K | ﹤0.01% | 2851 |
|
|
2024
Q4 | $366K | Sell |
22,247
-109
| -0.5% | -$2.15K | ﹤0.01% | 2864 |
|
|
2024
Q3 | $552K | Sell |
22,356
-1,875
| -8% | -$48.6K | ﹤0.01% | 2637 |
|
|
2024
Q2 | $614K | Sell |
24,231
-17
| -0.1% | -$441 | ﹤0.01% | 2530 |
|
|
2024
Q1 | $616K | Sell |
24,248
-951
| -4% | -$23K | ﹤0.01% | 2532 |
|
|
2023
Q4 | $571K | Sell |
25,199
-832
| -3% | -$17.2K | ﹤0.01% | 2585 |
|
|
2023
Q3 | $485K | Sell |
26,031
-25,682
| -50% | -$533K | ﹤0.01% | 2629 |
|
|
2023
Q2 | $1.34M | Buy |
51,713
+2,391
| +5% | +$64K | ﹤0.01% | 2143 |
|
|
2023
Q1 | $1.42M | Buy |
49,322
+3,497
| +8% | +$104K | ﹤0.01% | 1983 |
|
|
2022
Q4 | $1.36M | Buy |
45,825
+508
| +1% | +$14.4K | ﹤0.01% | 1989 |
|
|
2022
Q3 | $1.08M | Buy |
45,317
+1,502
| +3% | +$34.6K | ﹤0.01% | 2092 |
|
|
2022
Q2 | $978K | Buy |
43,815
+759
| +2% | +$16.9K | ﹤0.01% | 2152 |
|
|
2022
Q1 | $1.08M | Buy |
43,056
+1,013
| +2% | +$30.9K | ﹤0.01% | 2102 |
|
|
2021
Q4 | $1.51M | Sell |
42,043
-307
| -0.7% | -$12.3K | ﹤0.01% | 2027 |
|
|
2021
Q3 | $1.8M | Sell |
42,350
-4,474
| -10% | -$184K | ﹤0.01% | 1968 |
|
|
2021
Q2 | $2.03M | Sell |
46,824
-3,902
| -8% | -$166K | ﹤0.01% | 1942 |
|
|
2021
Q1 | $2.07M | Buy |
50,726
+2,181
| +4% | +$82.7K | ﹤0.01% | 1890 |
|
|
2020
Q4 | $2.2M | Buy |
48,545
+4,854
| +11% | +$184K | ﹤0.01% | 1805 |
|
|
2020
Q3 | $1.55M | Sell |
43,691
-2,893
| -6% | -$104K | ﹤0.01% | 1813 |
|
|
2020
Q2 | $1.76M | Sell |
46,584
-3,562
| -7% | -$117K | ﹤0.01% | 1801 |
|
|
2020
Q1 | $1.45M | Buy |
50,146
+2,507
| +5% | +$101K | ﹤0.01% | 1716 |
|
|
2019
Q4 | $2.47M | Buy |
47,639
+2,756
| +6% | +$160K | ﹤0.01% | 1680 |
|
|
2019
Q3 | $2.46M | Buy |
44,883
+1,765
| +4% | +$90.6K | ﹤0.01% | 1618 |
|
|
2019
Q2 | $1.75M | Buy |
43,118
+580
| +1% | +$21.1K | ﹤0.01% | 1819 |
|
|
2019
Q1 | $1.29M | Buy |
42,538
+366
| +0.9% | +$12.5K | ﹤0.01% | 1914 |
|
|
2018
Q4 | $1.42M | Buy |
42,172
+6,080
| +17% | +$219K | ﹤0.01% | 1845 |
|
|
2018
Q3 | $1.52M | Buy |
36,092
+244
| +0.7% | +$9.64K | ﹤0.01% | 1806 |
|
|
2018
Q2 | $1.15M | Buy |
35,848
+1,972
| +6% | +$81.2K | ﹤0.01% | 1950 |
|
|
2018
Q1 | $1.68M | Buy |
33,876
+695
| +2% | +$39.3K | ﹤0.01% | 1702 |
|
|
2017
Q4 | $1.79M | Buy |
33,181
+4,836
| +17% | +$268K | ﹤0.01% | 1687 |
|
|
2017
Q3 | $1.64M | Buy |
28,345
+625
| +2% | +$32.7K | ﹤0.01% | 1727 |
|
|
2017
Q2 | $1.37M | Buy |
27,720
+96
| +0.3% | +$4.42K | ﹤0.01% | 1779 |
|
|
2017
Q1 | $1.2M | Buy |
27,624
+8,169
| +42% | +$390K | ﹤0.01% | 1831 |
|
|
2016
Q4 | $953K | Buy |
19,455
+520
| +3% | +$24K | ﹤0.01% | 1875 |
|
|
2016
Q3 | $906K | Buy |
18,935
+1,265
| +7% | +$62.5K | ﹤0.01% | 1866 |
|
|
2016
Q2 | $948K | Sell |
17,670
-905
| -5% | -$42.6K | ﹤0.01% | 1814 |
|
|
2016
Q1 | $831K | Buy |
18,575
+585
| +3% | +$23.7K | ﹤0.01% | 1911 |
|
|
2015
Q4 | $686K | Buy |
17,990
+1,210
| +7% | +$46.3K | ﹤0.01% | 2048 |
|
|
2015
Q3 | $534K | Buy |
16,780
+191
| +1% | +$6.66K | ﹤0.01% | 2180 |
|
|
2015
Q2 | $548K | Buy |
16,589
+75
| +0.5% | +$2.67K | ﹤0.01% | 2265 |
|
|
2015
Q1 | $680K | Buy |
16,514
+2,025
| +14% | +$81.9K | ﹤0.01% | 2106 |
|
|
2014
Q4 | $590K | Sell |
14,489
-350
| -2% | -$13.7K | ﹤0.01% | 2176 |
|
|
2014
Q3 | $544K | Buy |
14,839
+450
| +3% | +$19.4K | ﹤0.01% | 2155 |
|
|
2014
Q2 | $667K | Sell |
14,389
-561
| -4% | -$24.9K | ﹤0.01% | 2085 |
|
|
2014
Q1 | $614K | Sell |
14,950
-590
| -4% | -$21.9K | ﹤0.01% | 2084 |
|
|
2013
Q4 | $593K | Buy |
15,540
+2,550
| +20% | +$78.7K | ﹤0.01% | 2150 |
|
|
2013
Q3 | $311K | Buy |
12,990
+18
| +0.1% | +$404 | ﹤0.01% | 2504 |
|
|
2013
Q2 | $221K | Buy |
+12,972
| New | +$187K | ﹤0.01% | 2915 |
|
Other funds holding ANIK
CP
BFM
CM
RhumbLine Advisers's ANIK Position: Q2 2026 in Review
RhumbLine Advisers reduced its Anika Therapeutics (ANIK) stake by 3.1% in Q2 2026, selling an estimated $7.66K and leaving 16,344 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3193.
RhumbLine Advisers first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.47M in Q4 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.
- RhumbLine Advisers held 16,344 shares of Anika Therapeutics worth $239K as of Q2 2026.
- RhumbLine Advisers sold 517 Anika Therapeutics shares in Q2 2026, an estimated $7.66K.
- Anika Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3193 holding.
- RhumbLine Advisers first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Anika Therapeutics position peaked at $2.47M in Q4 2019.
- 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.